Molecularly targeted agents for renal cell carcinoma: the next generation.
With the approval of several molecularly targeted agents over the past few years, the landscape of renal cell carcinoma (RCC) management has drastically changed. Response rates and survival have improved with these new agents compared to the previous standard of cytokine-based therapy. Many new agents are in various stages of development, and how these novel therapies will be incorporated into the paradigm of RCC treatment is yet to be determined. The development of optimal sequencing and combinations of these drugs is important to improving patient outcomes and overcoming resistance mechanisms.